Literature DB >> 11520474

Addition of a frequency-weighted score to the Behavioral Pathology in Alzheimer's Disease Rating Scale: the BEHAVE-AD-FW: methodology and reliability.

I M Monteiro1, I Boksay, S R Auer, C Torossian, S H Ferris, B Reisberg.   

Abstract

The Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD) is a well-established instrument, designed to assess potentially remediable behavioral symptoms in Alzheimer's disease (AD) patients as well as to evaluate treatment outcome. It consists of 25 symptoms grouped into seven categories. Each symptom is scored on the basis of severity on a four-point scale. A knowledgeable caregiver is queried and items are scored on the basis of symptoms noted in the preceding two weeks. Reliability, construct validity and criterion validity data for the BEHAVE-AD have previously been published. Because of the significance of psychopathology in dementia, it is necessary to optimally describe and define the nature, magnitude and prevalence of behavioral symptomatology. Accordingly, a frequency component was added to each of the 25 items of the BEHAVE-AD scale. The objective of the present report is to describe this new Behavioral Pathology in Alzheimer's Disease Frequency-Weighted Severity Scale (BEHAVE-AD-FW) and to establish its inter-rater reliability. In this investigation the BEHAVE-AD-FW scale was administered to caregivers of 28 patients with either mildly impaired cognitive function or a dementia diagnosis. Two clinicians separately and independently rated the responses. Analyses determined that the intraclass correlation coefficients (ICCs) for the frequency component varied between 0.86 and 0.97 for each of the seven BEHAVE-AD categories (p(s) < 0.001). ICCs for the frequency-weighted scores (item severity score x item frequency score) ranged from 0.69 to 0.98 for the seven symptom categories (p(s) < 0.001). For the BEHAVE-AD-FW total scores, the ICC was 0.91 (P < 0.001). These results indicate that the frequency-weighted component is a reliable addition to the BEHAVE-AD scale.

Entities:  

Mesh:

Year:  2001        PMID: 11520474     DOI: 10.1016/s0924-9338(00)00524-1

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  13 in total

Review 1.  The BEHAVE-AD assessment system: a perspective, a commentary on new findings, and a historical review.

Authors:  Barry Reisberg; Isabel Monteiro; Carol Torossian; Stefanie Auer; Melanie B Shulman; Santosh Ghimire; Istvan Boksay; Francoise Guillo BenArous; Ricardo Osorio; Aninditha Vengassery; Sheema Imran; Hussam Shaker; Sadaf Noor; Shazia Naqvi; Sunnie Kenowsky; Jinfeng Xu
Journal:  Dement Geriatr Cogn Disord       Date:  2014-04-07       Impact factor: 2.959

2.  Methodological Aspects of the Phase II Study AFF006 Evaluating Amyloid-beta -Targeting Vaccine AFFITOPE® AD02 in Early Alzheimer's Disease - Prospective Use of Novel Composite Scales.

Authors:  S Hendrix; N Ellison; S Stanworth; L Tierney; F Mattner; W Schmidt; B Dubois; A Schneeberger
Journal:  J Prev Alzheimers Dis       Date:  2015-06

3.  Comprehensive, Individualized, Person-Centered Management of Community-Residing Persons with Moderate-to-Severe Alzheimer Disease: A Randomized Controlled Trial.

Authors:  Barry Reisberg; Yongzhao Shao; James Golomb; Isabel Monteiro; Carol Torossian; Istvan Boksay; Melanie Shulman; Sloane Heller; Zhaoyin Zhu; Ayesha Atif; Jaskirat Sidhu; Alok Vedvyas; Sunnie Kenowsky
Journal:  Dement Geriatr Cogn Disord       Date:  2017-01-26       Impact factor: 2.959

4.  Mental health care for older adults: recent advances and new directions in clinical practice and research.

Authors:  Charles F Reynolds; Dilip V Jeste; Perminder S Sachdev; Dan G Blazer
Journal:  World Psychiatry       Date:  2022-10       Impact factor: 79.683

5.  Dementia service centres in Austria: A comprehensive support and early detection model for persons with dementia and their caregivers - theoretical foundations and model description.

Authors:  Stefanie R Auer; Edith Span; Barry Reisberg
Journal:  Dementia (London)       Date:  2013-10-17

6.  Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD).

Authors:  Stephane Nave; Rachelle S Doody; Mercè Boada; Timo Grimmer; Juha-Matti Savola; Paul Delmar; Meike Pauly-Evers; Tania Nikolcheva; Christian Czech; Edilio Borroni; Benedicte Ricci; Juergen Dukart; Marie Mannino; Tracie Carey; Emma Moran; Inma Gilaberte; Nicoletta Milani Muelhardt; Irene Gerlach; Luca Santarelli; Susanne Ostrowitzki; Paulo Fontoura
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

7.  Fear of Falling and Cognitive Impairments in Elderly People with Hip Fractures.

Authors:  Mari Kasai; Kenichi Meguro; Hiroshi Ozawa; Keiichi Kumai; Hideki Imaizumi; Hanae Minegishi; Hideki Oi; Akira Oizumi; Masahiro Yamashiro; Michimasa Matsuda; Masahiko Tanaka; Eiji Itoi
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2017-11-15

8.  DEMDATA: The Austrian-Czech institutional long term care project - design and protocol of a two-centre cross sectional study.

Authors:  Stefanie Auer; Elisabeth Linsmayer; Anna Beránková; Patrick Pascher; Bernadette Firlinger; Doris Prischl; Paulina Ratajczak; Edith Span; Iva Holmerova
Journal:  BMC Health Serv Res       Date:  2017-04-20       Impact factor: 2.655

9.  Cross-sectional study of prevalence of dementia, behavioural symptoms, mobility, pain and other health parameters in nursing homes in Austria and the Czech Republic: results from the DEMDATA project.

Authors:  Stefanie R Auer; Margit Höfler; Elisabeth Linsmayer; Anna Beránková; Doris Prieschl; Paulina Ratajczak; Michal Šteffl; Iva Holmerová
Journal:  BMC Geriatr       Date:  2018-08-13       Impact factor: 3.921

10.  Data of a sub-analysis of the DEMDATA study: characteristics of Austrian and Czech nursing homes residents.

Authors:  Margit Höfler; Paulina Ratajczak; Anna Beránková; Doris Prieschl; Michal Šteffl; Iva Holmerová; Stefanie R Auer
Journal:  BMC Res Notes       Date:  2019-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.